Brendon L Neuen

Aug 3, 2024 | jacc.org | Muthiah Vaduganathan |Brendon L Neuen |Finnian McCausland |Pardeep S. Jhund

References1. "Cardiovascular-kidney-metabolic overlap in heart failure with mildly reduced or preserved ejection fraction: a trial-level analysis". J Am Coll Cardiol . 2024;84:2: 223-228. 2. "Kidney function and outcomes in patients hospitalized with heart failure". J Am Coll Cardiol . 2021;78:4: 330-343. 3.

Jul 8, 2024 | thelancet.com | Ellen M. Apperloo |Brendon L Neuen |Robert Fletcher |Niels Jongs

SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the benefits of SGLT2 inhibitors are consistent in patients receiving and not receiving GLP-1 receptor agonists. We conducted a collaborative meta-analysis of trials included in the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium, restricted to participants with diabetes.

Apr 15, 2024 | ahajournals.org | Brendon L Neuen |Katherine R. Tuttle |Muthiah Vaduganathan

REFERENCES1. Rossing P, Caramori ML, Chan JC, Heerspink HJ, Hurst C, Khunti K, Liew A, Michos ED, Navaneethan SD, Olowu WA, . KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease.Kidney Int. 2022; 102:S1–S127. doi: 10.1016/j.kint.2022.06.008CrossrefMedlineGoogle Scholar2. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, . Management of hyperglycemia in type 2 diabetes, 2022.

Apr 6, 2024 | jacc.org | Safia Chatur |Brendon L Neuen |Brian Claggett |Iris E. Beldhuis

Introduction Heart failure (HF) and chronic kidney disease (CKD) frequently coexist1 and jointly contribute to increased risk of cardiovascular (CV) events, progression of kidney disease, and mortality.2 The recently released 2024 Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines strongly underscore the importance of robust estimation of kidney risk.3 Both lower estimated glomerular filtration rate (eGFR) values and higher levels of albuminuria predict adverse...

Feb 13, 2024 | reference.medscape.com | Brendon L Neuen

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. C3 glomerulopathy (C3G) is a group of rare glomerular diseases characterized by dysregulation of the alternative complement pathway leading to complement deposition, glomerular inflammation, and injury.